XENT / Intersect ENT Inc (NASDAQ) - Forecast, Price Target, Estimates, Predictions

Intersect ENT Inc
US ˙ NASDAQ ˙ US46071F1030
THIS SYMBOL IS NO LONGER ACTIVE

Projected Stock Price
No data available.
Projected Revenue

No data available.
Projected Earnings Per Share

No data available.
Price Target

Update Frequency: Monthly

Record Date Projection Date High Low Median Average
2023-03-27 2024-03-27 29.66 28.53 28.82 28.82
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for Intersect ENT Inc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Why Are Analyst Ratings important?

In addition to being able to interpret financial data, stock analysts have connections within the companies they cover that give them access to information retail investors do not have.

Therefore, analyst ratings can help you find opportunities in the market. However, they are guidelines more than recommendations. This is why it’s important to look at analyst ratings over a period of time.

If analysts change their ratings frequently, you should pay close attention to the company’s fundamentals. For example, has there been a significant change to the company’s earnings growth and/or debt?

You should also pay attention to the number of analysts covering a stock over the course of a year. In general, the more analysts who cover the stock give the consensus rating more credibility, but each individual rating less overall weight.

How to Use Analyst Ratings ?

Analyst ratings are one data point for you to consider. Here are some strategies you can use to fine tune your research.

Look at more than one analyst and don’t hesitate to look at analysts that have differing views. This can help challenge any preconceived ideas you have about a stock and point out ways in which your thesis for owning or avoiding a stock may have changed.

Compare a stock’s rating with other stocks in its industry or sector. In some cases, a stock is simply superior to others in its sector. However, at other times, it could be overvalued based on investor sentiment instead of fundamentals.

How are the Fintel Analyst Ratings different?

Analyst ratings by Fintel are presented in close to real-time to stay ahead of generalized information flow. Combined with target price estimates and revenue estimates for the company you have greater accuracy despite market volatility.

Date Analyst Prior Latest
Recommendation
Action
2021-08-12 SVB Leerink Outperform Market Perform Downgrade
2021-08-10 BTIG Buy Neutral Downgrade
2021-08-09 Guggenheim Buy Neutral Downgrade
2021-08-09 Canaccord Genuity Buy Hold Downgrade
2021-06-24 SVB Leerink Market Perform Outperform Upgrade
2021-05-11 SVB Leerink Market Perform Maintains
2021-03-10 SVB Leerink Market Perform Maintains
2021-01-11 Canaccord Genuity Hold Buy Upgrade
2020-12-03 SVB Leerink Market Perform Maintains
2020-11-19 BTIG Neutral Buy Upgrade
2020-11-03 SVB Leerink Market Perform Maintains
2020-10-08 JP Morgan Overweight Neutral Downgrade
2020-08-05 SVB Leerink Market Perform Maintains
2020-07-15 SVB Leerink Market Perform Maintains
2020-06-29 SVB Leerink Market Perform Maintains
2020-06-24 Oppenheimer Perform Initiate
2020-05-12 SVB Leerink Market Perform Maintains
2020-05-12 JP Morgan Overweight Maintains
2020-05-12 Canaccord Genuity Buy Hold Downgrade
2020-04-15 B of A Securities Buy Underperform Downgrade
2019-12-20 JP Morgan Overweight Maintains
2019-08-02 Piper Jaffray Overweight Neutral Downgrade
2019-08-02 Guggenheim Buy Neutral Downgrade
2019-07-10 Northland Securities Underperform Market Perform Upgrade
2019-06-21 Berenberg Buy Hold Downgrade
2019-05-07 SVB Leerink Outperform Market Perform Downgrade
2019-05-07 Northland Market Perform Underperform Downgrade
2019-02-26 Canaccord Genuity Buy Buy Maintains
2018-01-02 JP Morgan Neutral Overweight Upgrade
2017-09-13 Canaccord Genuity Buy Maintains
2017-08-02 Deutsche Bank Buy Maintains
2017-05-31 Northland Securities Outperform Market Perform Downgrade
2017-03-06 Deutsche Bank Hold Buy Upgrade
2016-12-07 Guggenheim Buy Initiate
2016-11-02 JP Morgan Overweight Neutral Downgrade
2016-10-06 Deutsche Bank Hold Initiate
2016-03-29 Northland Securities Outperform Initiate
2015-12-18 Bank of America Buy Initiate
2015-11-05 Leerink Swann Outperform Maintains
2015-09-29 PiperJaffray Overweight Maintains
2015-06-30 Cantor Fitzgerald Buy Initiate
2015-06-17 Leerink Swann Outperform Maintains
2015-06-09 Canaccord Genuity Buy Maintains
2015-05-07 Leerink Swann Outperform Maintains
2015-04-09 CRT Capital Buy Initiate
2015-03-16 Canaccord Genuity Buy Initiate
2014-08-18 PiperJaffray Overweight Initiate
2014-08-18 Leerink Swann Outperform Initiate
2014-08-18 JP Morgan Overweight Initiate
Revenue Estimates
No data available.
Earnings Estimates
No data available.
EBITDA Estimates
No data available.
EBIT Estimates
No data available.
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista